HK1257229A1 - Cck2r-药物偶联物 - Google Patents

Cck2r-药物偶联物 Download PDF

Info

Publication number
HK1257229A1
HK1257229A1 HK18116265.4A HK18116265A HK1257229A1 HK 1257229 A1 HK1257229 A1 HK 1257229A1 HK 18116265 A HK18116265 A HK 18116265A HK 1257229 A1 HK1257229 A1 HK 1257229A1
Authority
HK
Hong Kong
Prior art keywords
cck2r
drug conjugates
pertains
disclosure
drugs
Prior art date
Application number
HK18116265.4A
Other languages
English (en)
Chinese (zh)
Inventor
Garth L. Parham
Melissa NELSON
Marilynn VETZEL
Christina M. DIRCKSEN
Joseph Anand Reddy
Christopher Paul Leamon
Iontcho Radoslavov Vlahov
Original Assignee
Endocyte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte, Inc. filed Critical Endocyte, Inc.
Publication of HK1257229A1 publication Critical patent/HK1257229A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18116265.4A 2015-08-14 2016-08-10 Cck2r-药物偶联物 HK1257229A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562205411P 2015-08-14 2015-08-14
US201562205411P 2015-08-14
US201562261227P 2015-11-30 2015-11-30
US201562261227P 2015-11-30
US201662323287P 2016-04-15 2016-04-15
US201662323287P 2016-04-15
PCT/US2016/046292 WO2017030859A1 (en) 2015-08-14 2016-08-10 Cck2r-drug conjugates

Publications (1)

Publication Number Publication Date
HK1257229A1 true HK1257229A1 (zh) 2019-10-18

Family

ID=58051970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116265.4A HK1257229A1 (zh) 2015-08-14 2016-08-10 Cck2r-药物偶联物

Country Status (6)

Country Link
US (1) US10500286B2 (enExample)
EP (1) EP3334447A4 (enExample)
JP (1) JP2018525399A (enExample)
CA (1) CA2995371A1 (enExample)
HK (1) HK1257229A1 (enExample)
WO (1) WO2017030859A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
AU2021466987B2 (en) * 2021-09-28 2025-11-20 Paul Scherrer Institut Method for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a compound targeting cck2-r, and compound for use in methods of selectively treating and/or imaging cancer
CN120554245A (zh) * 2025-07-30 2025-08-29 辽宁众辉生物科技有限公司 一种氟吡菌酰胺中间体n-乙酰氧基甲基-2-三氟甲基苯甲酰胺的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776814B2 (en) * 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
US8431714B2 (en) * 2007-04-16 2013-04-30 University Of Southern California Synthesis of drug conjugates via reaction with epoxide-containing linkers
WO2013126797A1 (en) * 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy

Also Published As

Publication number Publication date
CA2995371A1 (en) 2017-02-23
WO2017030859A1 (en) 2017-02-23
JP2018525399A (ja) 2018-09-06
US10500286B2 (en) 2019-12-10
EP3334447A1 (en) 2018-06-20
US20180228909A1 (en) 2018-08-16
EP3334447A4 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
SG10201803042PA (en) Anti-tim-3 antibodies
EP3154574A4 (en) Homogenous antibody drug conjugates via enzymatic methods
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2019007020A (es) Anticuerpos il-11.
MY193806A (en) Affinity-oligonucleotide conjugates and uses thereof
EP3315608A4 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
EP3711780A3 (en) Anti-ptk7 antibody-drug conjugates
EP3334500A4 (en) MULTILIGAND-ACTIVE CONJUGATES AND USES THEREOF
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
EP3491026A4 (en) HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
MX2019007021A (es) Anticuerpos il-11ra.
EP3207147A4 (en) Bipartite and tripartite signaling immune cells
EP3186277A4 (en) Antibodies, compositions, and uses
EP3250238A4 (en) Antibody drug conjugates
EP3253212A4 (en) Antibody drug conjugates
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
EP3100731A4 (en) Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
MX2017009937A (es) Cepas fungicas y metodos de uso.
EP3186217A4 (en) Polyethers, polyamines, polythioethers, and methods for making same
EP3148565A4 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
GB201614162D0 (en) Antibodies, uses thereof and conjugates thereof
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
AU2016349786C1 (en) Anti-CD3-folate conjugates and their uses
HK1257229A1 (zh) Cck2r-药物偶联物